Management of COVID-19 disease in pregnancy poses unique challenges, as it requires consideration of maternal physiologic changes, fetal and placental physiology, and a multidisciplinary approach to decision-making, particularly in patients with severe or critical disease. Though the majority of pregnant patients who test positive for SARS-CoV-2 remain asymptomatic or have mild disease and recover without undergoing delivery [1], a significant number develop critical illness and may have prolonged and complex disease courses [2].The prevalence of SARS-CoV-2 infection in pregnant women approximates the overall population prevalence. Based on data from the H1N1 influenza and SARS pandemics during which pregnant women were at a higher risk of infection and had worse clinical outcomes [3,4], it was anticipated that parturients during the SARS-CoV-2 outbreak would follow similar patterns.Current studies, however, have found that pregnant women have similar rates of infection with SARS-CoV-2 and clinical courses and outcomes when compared with reproductive-aged non-pregnant women [5,6]. In a systematic review of 538 pregnancies from China, Italy, and the United States, 15% of patients met criteria for severe disease, and only 1.4% were considered critical. This is in contrast to the SARS, H1N1, and MERS pandemics, during which pregnant women suffered disproportionately from critical respiratory disease and mortality [4,7].